Vysis®UroVysion for the detection of urothelial carcinoma
- 1 July 2003
- journal article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 3 (4), 507-519
- https://doi.org/10.1586/14737159.3.4.507
Abstract
For decades, cystoscopy and urine cytology have been the mainstay for monitoring superficial urothelial carcinoma patients for tumor recurrence. However, urine cytology has poor sensitivity for urothelial carcinoma and, consequently, numerous investigators have been endeavoring to develop more sensitive assays for the detection of urothelial carcinoma. This article presents an overview of the types of new assays that have been developed for urothelial carcinoma detection but focuses primarily on the features and performance of a new fluorescence in situ hybridization assay for urothelial carcinoma detection known as Vysis UroVysion.Keywords
This publication has 11 references indexed in Scilit:
- Clinical Evaluation of a Multi-target Fluorescent in Situ Hybridization Assay for Detection of Bladder CancerJournal of Urology, 2002
- DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urineCancer, 2002
- Chromosome segregation and cancer: cutting through the mysteryNature Reviews Cancer, 2001
- URINE BASED MARKERS OF UROLOGICAL MALIGNANCYJournal of Urology, 2001
- A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMAJournal of Urology, 2000
- The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in UrineThe Journal of Molecular Diagnostics, 2000
- Detection of bladder cancer recurrence by microsatellite analysis of urineNature Medicine, 1997
- Molecular Detection of Primary Bladder Cancer by Microsatellite AnalysisScience, 1996
- Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nucleiCytometry, 1994
- Genetic alterations in bladder cancerThe Lancet, 1993